Results 11 to 20 of about 121,431 (264)
ImmunoMedicine, 2022 Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies ...
Yue Huang, Mi Shao, Yiyun Wang, He Huang
doaj +1 more source
Critical Care Explorations, 2021 BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH +4 more
doaj +1 more source
Chimeric antigen receptors that trigger phagocytosis [PDF]
eLife, 2018 Abstract Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity, and suggests that applying CAR strategies to other immune cell lineages may be beneficial. Here, we engineered a family of Chimeric Antigen Receptors
Meghan A Morrissey +6 more
openaire +5 more sources
An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells
Translational Research in Urology, 2020 Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh +1 more
doaj +1 more source
CAR-T cell therapy for hematological malignancies: History, status and promise
Heliyon, 2023 For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang +3 more
doaj +1 more source
[Chimeric antigen receptor T cells].
Bulletin du cancer, 2021 Chimeric antigen receptor T-cell (CAR T-cells) therapies which are genetically modified T lymphocyte targeting tumor antigens have modified therapeutic landscape in hematology. Aggressive B cells lymphoma are currently treated in daily practice with anti-CD19 CAR T.
Bories, Pierre, Ysebaert, Loïc
openaire +2 more sources
Chimeric Antigen Receptor Therapy
New England Journal of Medicine, 2018 Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
Carl H. June, Michel Sadelain
openaire +3 more sources
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma [PDF]
Current Treatment Options in Oncology, 2022 Opinion statementThe therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process.
Arushi Khurana, Yi Lin
openaire +2 more sources
Engineering and Design of Chimeric Antigen Receptors [PDF]
Molecular Therapy - Methods & Clinical Development, 2019 T cells engineered with chimeric antigen receptors (CARs) have emerged as a potent new class of therapeutics for cancer, based on their remarkable potency in blood cancers. Since the first clinical reports of their efficacy emerged 7 years ago, investigators have focused on the mechanisms and properties that make CARs effective or toxic, and their ...
Sonia Guedan +3 more
openaire +3 more sources
Chimeric antigen receptor T cell
Indian Journal of Pharmacology, 2022 During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer ...
Singh, Surjit +4 more
openaire +2 more sources